Xtant Medical Holdings

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. Thecompany was founded in 2006 and is headquartered in Belgrade, MT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xtant Medical Holdings reports robust Q1 growth and raises guidance

Xtant Medical Holdings delivered strong revenue growth in Q1 2024, with a focus on strategic initiatives for future expansion and market penetration.
While facing challenges in supply chain and product cannibalization, the company's emphasis on new products and acquisitions bodes well for long-term growth.
With an increased revenue guidance for 2024 and a positive adjusted EBITDA, Xtant is poised for accelerated organic growth and improved financial performance.

Xtant Medical Holdings reports robust Q2 growth and strategic focus

Xtant Medical Holdings is on track to achieve full-year revenue guidance of $116 million to $120 million.
The company's focus on new products, acquisitions, and operational efficiency bodes well for long-term growth.
Despite challenges in organic growth and net loss, Xtant is strategically positioned for sustainable expansion.

Xtant Medical Holdings reports solid Q3 growth amidst product challenges

Xtant Medical Holdings showed growth in Q3 despite challenges with product delays.
The company is focused on profitability, self-sustainability, and doubling in size by 2024.
Strategic moves like bringing manufacturing in-house and new product releases position Xtant for future growth.
Anticipates revenue growth, margin improvement, and aims for EBITDA positivity in Q4.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. The company was founded in 2006 and is headquartered in Belgrade, MT.

BELGRADE, Mont., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it completed the acquisition of certain assets and liabilities related to the domestic and international biologics and spinal fixation offerings of Surgalign Holdings, Inc. under a Bankruptcy Court supervised process for $5 million, plus assumed liabilities, in an all-cash transaction.

Xtant Medical Completes Acquisition of Surgalign's Hardware and Biologics Business

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2023 Earnings Conference Call August 1, 2023 9:00 AM ET Company Participants Matt Steinberg - IR Sean Browne - CEO Scott Neils - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings. You're welcome Xtant Medical's Second Quarter 2023 Financial Results Conference Call.

Xtant Medical Holdings, Inc. (XTNT) Q2 2023 Earnings Call Transcript

Raises 2023 Annual Revenue Guidance to $75 Million - $77 Million BELGRADE, Mont., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2023.

Xtant Medical Announces Second Quarter Revenue Growth of 32%

Acquisition to Enhance Xtant's Growing Spinal Fusion Devices Portfolio BELGRADE, Mont., July 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it was the successful bidder for certain assets and liabilities related to the domestic and international biologics and spinal fixation offerings of Surgalign Holdings, Inc. Xtant's initial bid, as set forth in the Asset Purchase Agreement, dated June 18, 2023, between Xtant and Surgalign, was the winning bid.

Xtant Medical Wins Auction for Surgalign's Hardware and Biologics Business

BELGRADE, Mont., July 25, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2023, before the open of the financial markets on Tuesday, August 1, 2023.

Xtant Medical to Issue Second Quarter 2023 Financial Results on August 1, 2023

BELGRADE, Mont., July 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $15 million private placement with accredited investors. The Company sold 20 million shares of common stock at a purchase price of $0.75 per share. After deducting fees and other estimated offering expenses, the Company received net proceeds of approximately $14.2 million.

Xtant Medical Announces Closing of $15 Million Private Placement

BELGRADE, Mont., July 03, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with accredited investors to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 20,000,000 shares of common stock at a purchase price of $0.75 per share, resulting in gross proceeds of $15 million.

Xtant Medical Announces $15 Million Private Placement

BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors.

Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Matt Steinberg - IR Sean Browne - CEO Scott Neils - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Kyle Rose - Canaccord Genuity Operator Greetings. You're welcome Xtant Medical's Q1 2023 financial results call.

Xtant Medical Holdings, Inc. (XTNT) Q1 2023 Earnings Call Transcript

Initiates Annual Revenue Guidance of $73 Million - $75 Million in Full Year 2023 BELGRADE, Mont., May 04, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2023.

Xtant Medical Announces First Quarter 2023 Revenue Growth of 38% and Full Year 2023 Revenue Guidance

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q4 2022 Earnings Conference Call March 7, 2023 9:00 AM ET Company Participants Matt Steinberg - IR, FINN Partners Sean Browne - President and Chief Executive Officer Scott Niels - Chief Financial Officer Conference Call Participants Operator Greetings and welcome to the Xtant Medical Fourth Quarter and Full Year 2022 Financial Results Conference Call [Operator Instructions]. As a reminder, this conference is being recorded.

Xtant Medical Holdings, Inc. (XTNT) Q4 2022 Earnings Call Transcript

BELGRADE, Mont., March 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2022.

Xtant Medical Announces Fourth Quarter and Full Year 2022 Financial Results

BELGRADE, Mont., March 03, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, before the open of the financial markets on Tuesday, March 7, 2023.

Xtant Medical to Issue Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

BELGRADE, Mont., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the Canaccord Musculoskeletal Conference, to be held on Tuesday, March 7, 2023 at 3:30 p.m. Pacific Time in Las Vegas.

Xtant Medical to Present at the Canaccord Musculoskeletal Conference on March 7, 2023

Company Sponsors Donate Life Float at Rose Parade for the Ninth Year

Xtant Medical Honors Donor Hero Asante Contreras on the Donate Life Rose Parade® Float

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q3 2022 Results Conference Call November 3, 2022 9:00 AM ET Company Participants Matt Steinberg - IR, FINN Partners Sean Browne - President and Chief Executive Officer Scott Niels - Chief Financial Officer Operator Greetings, and welcome to the Xtant Medical Q3 2022 Financial Results Conference Call [Operator Instructions]. As a reminder, this conference is being recorded.

Xtant Medical Holdings, Inc. (XTNT) Q3 2022 Earnings Call Transcript

BELGRADE, Mont., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2022.

Xtant Medical Announces Third Quarter 2022 Financial Results

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Matt Steinberg - IR, Lazar FINN Partners Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Operator Greetings and welcome to the Xtant Medical Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q2 2022 Results Earnings Call Transcript

BELGRADE, Mont., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2022.

Xtant Medical Announces Second Quarter 2022 Financial Results

BELGRADE, Mont., July 28, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2022, before the open of the financial markets on Thursday, August 4, 2022.

Xtant Medical to Issue Second Quarter 2022 Financial Results on August 4, 2022

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2022 Earnings Conference Call May 5, 2022 9:00 AM ET Company Participants Matt Steinberg - Investor Relations, Lazar FINN Partners Sean Browne - President and Chief Executive Officer Scott Neils - Interim Chief Financial Officer Operator Greetings and welcome to the Xtant Medical First Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q1 2022 Results - Earnings Call Transcript

BELGRADE, Mont., May 05, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2022.

Xtant Medical Announces First Quarter 2022 Financial Results

BELGRADE, Mont., May 02, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Chief Financial Officer, effective June 1, 2022.

Xtant Medical Appoints Scott Neils as Chief Financial Officer

BELGRADE, Mont., April 28, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2022, before the open of the financial markets on Thursday, May 5, 2022.

Xtant Medical to Issue First Quarter 2022 Financial Results on May 5, 2022

BELGRADE, Mont., March 15, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, President and Chief Executive Officer, will present at the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022, at 2:00 p.m. Central Time in Chicago.

News for Xtant Medical Holdings Stock (XTNT)